Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17560478 | 1.00 | HTR6 (0.36) | HTR6KMT2APOLBALDH1A1GAA | |
| SCHEMBL17570145 | 1.00 | HTR6 (0.36) | HTR6KMT2APOLBALDH1A1GAA | |
| SCHEMBL19426643 | 0.86 | KDM4E (0.39) | KMT2APOLBALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL17560601 | 0.85 | NR1H4 (0.33) | MAPKAPK2NR1H4MAP4K4 | |
| SCHEMBL17560600 | 0.85 | NR1H4 (0.33) | MAPKAPK2NR1H4MAP4K4 | |
| SCHEMBL19271237 | 0.83 | HTR6 (0.39) | HTR6KMT2APOLBALDH1A1GAA | |
| SCHEMBL17560319 | 0.82 | RAB9A (0.48) | KMT2APOLBALDH1A1GAANPC1 | |
| SCHEMBL17569413 | 0.82 | MAPT (0.49) | KMT2APOLBALDH1A1NPC1RAB9A | |
| SCHEMBL19275673 | 0.82 | MAPT (0.49) | KMT2APOLBALDH1A1NPC1RAB9A | |
| SCHEMBL1667284 | 0.82 | KMT2A (0.44) | HTR6KMT2APOLBALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9944641-B2 | Isoquinolinone derivatives useful in the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2018-04-17 | — | — | US | disclosed |
| US-9944641-B2 | Isoquinolinone derivatives useful in the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2018-04-17 | — | — | US | disclosed |
| US-20170240544-A1 | ISOQUINOLINONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2017-08-24 | — | — | US | disclosed |
| US-20170240544-A1 | ISOQUINOLINONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2017-08-24 | — | — | US | disclosed |
| EP-3189051-A1 | ISOQUINOLINONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Pierre Fabre Médicament (FR) | 2017-07-12 | — | — | EP | disclosed |
| WO-2016034642-A1 | ISOQUINOLINONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2016-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240544-A1 | ISOQUINOLINONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | TP53, KRAS, AQP1 | HTR6 4054/4885KMT2A 1365/4885POLB 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.